bpc-157 thymosin / Beta-4 Peptide Therapy Benefits: BPC-157, TA-1

In studies involving inflammatory bowel disease (IBD), the peptide has been shown to mitigate intestinal inflammation, reduce lesion size, and promote the regeneration of the epithelial lining

A key observation was the production of anti-cagrilintide antibodies, with increased incidence correlating with higher doses and prolonged exposure, affecting 46% to 73% of participants by week 26

Both raise IGF-1, both carry the GH axiss theoretical risks, and only tesamorelins risk profile has actually been characterized in trials

No complicated preparation

GLP-1 is released naturally by the gut and stimulates insulin release, lowers blood sugar levels, and reduces appetite

Petersburg Institute of Bioregulation and Gerontology, rests on the premise that short peptides may act as signalling molecules regulating tissue activity